Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

Abstract Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b study in East Asian patients with AML or MDS, condu...

Full description

Bibliographic Details

Published in:	Journal of Hematology & Oncology
Main Authors:	Hiroshi Handa, June-Won Cheong, Yasushi Onishi, Hiroatsu Iida, Yukio Kobayashi, Hyeoung-Joon Kim, Tzeon-Jye Chiou, Koji Izutsu, Olga Tsukurov, Xiaofei Zhou, Helene Faessel, Ying Yuan, Farhad Sedarati, Douglas V. Faller, Akiko Kimura, Shang-Ju Wu
Format:	Article
Language:	English
Published:	BMC 2022-05-01
Subjects:	AML MDS Pevonedistat Phase 1/1b East Asian
Online Access:	https://doi.org/10.1186/s13045-022-01264-w